297 Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers
Main Authors: | David Turner, John Glod, Alexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, E Andres Houseman, Shan Zhong, Jaegil Kim, Laura Johnson, Jenna Tress, Aisha Hasan, Victoria Chiou, Naimish Pandya, Dejka Araujo, Warren Chow, Mihaela Druta, George Demetri, Brian Van Tine |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
96 Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo
by: Sara Brett, et al.
Published: (2020-11-01) -
Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
by: Zhitao Ying, et al.
Published: (2021-02-01) -
Nachlass 297: Sammlung Wustmann
by: Fuchs, Thomas
Published: (2011) -
Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor
by: Jocelyn Joseph, et al.
Published: (2019-11-01) -
RECL 297 - 26-Jul-85
Published: (2011)